

ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT

Rapilysin 10 U powder and solvent for solution for injection.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

1 vial contains 0.56 g powder for solution for injection with 10 U reteplase (INN)

1 prefilled syringe contains 10 ml water for injections.

The reconstituted solution contains 1 U reteplase per ml.

Potency of reteplase is expressed in units (U) by using a reference standard which is specific for reteplase and is not comparable with units used for other thrombolytic agents.

For excipients see section 6.1.

3. PHARMACEUTICAL FORM

Powder and solvent for solution for injection.

Appearance: white powder (lyophilisate) and clear colourless liquid (water for injection).

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

Rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left Bundle Branch Block within 12 hours after the onset of AMI symptoms.

4.2 Posology and method of administration

Treatment with reteplase should be initiated as soon as possible after the onset of AMI symptoms.

Rapilysin should be prescribed by physicians experienced in the use of thrombolytic treatment and with the facilities to monitor its use.

Reteplase is supplied as a freeze-dried substance in vials. The lyophilisate is reconstituted with the contents of the accompanying syringe (see chapter 6.6 Instructions for use and handling).

The reconstituted solution must be used immediately. Visual inspection of the solution is necessary after reconstitution. Only clear, colourless solutions should be injected. If the solution is not clear and colourless it should be discarded.

Heparin and Rapilysin are incompatible when combined in solution. Other incompatibilities may also exist. No other medication should be added to the injection solution (see below and 6.2. Incompatibilities). Rapilysin should be injected preferably through an intravenous line whose sole purpose is the injection of Rapilysin. No other medication should be injected through the line reserved for Rapilysin, neither at the same time, nor prior to, nor following Rapilysin injection. This applies to all products including heparin, and acetylsalicylic acid, which should be administered before and following the administration of reteplase to reduce the risk of re-thrombosis.

In those patients where the same line has to be used, this line (including Y-line) must be flushed thoroughly with 0.9 % sodium chloride or 5 % dextrose solution prior to and following the Rapilysin injection.

Dosage of Rapilysin

Rapilysin is administered as a 10 U bolus dose followed by a second 10 U bolus dose 30 minutes later (double bolus).

Each bolus is administered as a slow intravenous injection within 2 minutes. Ensure that the injection is not mistakenly given paravenously.

Heparin and acetylsalicylic acid should be administered before and following the administration of Rapilysin to reduce the risk of rethrombosis.

Dosage of Heparin

The recommended dose of heparin is 5000 I.U. given as a bolus injection prior to reteplase therapy followed by an infusion of 1000 I.U. per hour starting after the second reteplase bolus. Heparin should be administered for at least 24 hours, preferably for 48 – 72 hours, aiming to keep aPTT values 1.5 to 2 times normal.

Dosage of Acetylsalicylic Acid

The initial dose of acetylsalicylic acid prior to thrombolysis should be at least 250 mg (250 – 350 mg) followed by 75 – 150 mg/day at least until discharge.

4.3 Contraindications

Rapilysin is contraindicated in patients with known hypersensitivity to the active substance (reteplase), polysorbate 80 or any of the other ingredients.

Because thrombolytic therapy increases the risk of bleeding, reteplase is contra-indicated in the following situations:

- known haemorrhagic diathesis
- patients with current concomitant therapy with oral anticoagulants (e.g. warfarin sodium)
- intracranial neoplasm, arteriovenous malformation or aneurysm
- neoplasm with increased bleeding risk
- history of cerebrovascular accident
- recent (< 10 days) prolonged and vigorous external heart massage
- severe uncontrolled hypertension
- active peptic ulceration
- portal hypertension (oesophageal varices)
- severe liver or renal dysfunction
- acute pancreatitis, pericarditis, bacterial endocarditis
- within 3 months of severe bleeding, major trauma or major surgery (e.g. coronary artery bypass graft, intracranial or intraspinal surgery or trauma), obstetrical delivery, organ biopsy, previous puncture of noncompressible vessels

4.4 Special warnings and special precautions for use

Each patient being considered for therapy with reteplase should be carefully evaluated. For information on product incompatibilities see section 4.2

Bleeding

The most common complication encountered during reteplase therapy is bleeding. In the following conditions the risks of reteplase therapy may be increased and should be weighed against the anticipated benefits:

- cerebrovascular disease
- systolic blood pressure at entry > 160 mmHg
- recent gastrointestinal or genitourinary bleeding (within 10 days)
- high likelihood of left heart thrombus, e.g. mitral stenosis with atrial fibrillation
- septic thrombophlebitis or occluded arteriovenous cannula at seriously infected site
- age over 75 years
- any other condition in which bleeding constitutes a significant hazard or would be particularly difficult because of its location

The concomitant use of heparin anticoagulation may contribute to bleeding. As fibrin is lysed during reteplase therapy, bleeding from recent puncture sites may occur. Therefore, thrombolytic therapy requires careful attention to all possible bleeding sites (including catheter insertion sites, arterial and venous puncture sites, cutdown sites and needle puncture sites). The use of rigid catheter as well as intramuscular injections and nonessential handling of the patient should be avoided during treatment with reteplase.

Caution should be employed when used with other drugs affecting haemostasis such as heparin, low-molecular-weight heparins, heparinoids, oral anticoagulants and antiplatelet agents other than acetylsalicylic acid, such as dipyridamole, ticlopidine, clopidogrel or glycoprotein IIb/IIIa receptor antagonists.

Should serious bleeding, in particular cerebral haemorrhage, occur any concomitant heparin should be terminated immediately. In addition, the second bolus of reteplase should not be given if the serious bleeding occurs before it is administered. In general, however, it is not necessary to replace the coagulation factors because of the relatively short half-life of reteplase. Most patients who have bleeding can be managed by interruption of thrombolytic and anticoagulant therapy, volume replacement and manual pressure applied to an incompetent vessel. Protamine should be considered if heparin has been administered within 4 hours of the onset of bleeding. In the patients who fail to respond to these conservative measures, judicious use of transfusion products may be indicated. Transfusions of cryoprecipitate, fibrinogen, fresh frozen plasma and platelets should be considered with clinical and laboratory reassessment after each administration. A target fibrinogen level of 1 g/l is desirable with cryoprecipitate or fibrinogen infusion.

At present, insufficient data in patients with a diastolic blood pressure > 100 mmHg prior to thrombolytic therapy are available for reteplase.

Arrhythmias

Coronary thrombolysis may result in arrhythmias associated with reperfusion. It is strongly recommended that antiarrhythmic therapy for bradycardia and/or ventricular tachyarrhythmias (e.g. ventricular tachycardia or fibrillation) be available when reteplase is administered.

Readministration

Since at present there is no experience with readministration of reteplase, the readministration is not recommended. However, no antibody formation to the reteplase molecule has been observed. If an anaphylactoid reaction occurs, the injection should be discontinued immediately and appropriate therapy should be initiated.

Use in children

Safety and effectiveness of reteplase in children have not been established. Treatment of children is not recommended.

4.5 Interaction with other medicinal products and other forms of interaction

No formal interaction studies with reteplase and drugs commonly administered in patients with AMI have been performed. Retrospective analyses of clinical studies did not reveal any clinically relevant interactions with drugs used concomitantly with reteplase in patients with acute myocardial infarction. Heparin, vitamin K antagonists and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole and abciximab) may increase the risk of bleeding if administered prior to, during or after reteplase therapy.

Attention should be paid to this effect especially during periods of low plasma fibrinogen (up to about 2 days after fibrinolytic therapy of AMI).

For information on product incompatibilities see section 4.2.

4.6 Pregnancy and lactation

There are no adequate data on the use of reteplase in pregnant women. The only relevant available animal data refer to studies performed in rabbits, which showed vaginal bleedings associated with abortions (see 5.3) The potential risk for humans is unknown.

Except in life-threatening situations, Rapilysin 10 U should not be used in pregnant women.

It is not known whether reteplase is excreted into breast milk. Breast milk should be discarded within the first 24 hours after thrombolytic therapy.

4.7 Effects on ability to drive and use machines

Not applicable

4.8 Undesirable effects

The frequency of the adverse drug reactions is described using the following convention:

Very common	> 1/10
Common	> 1/100, < 1/10
Uncommon	> 1/1,000, < 1/100
Rare	> 1/10,000, < 1/1,000
Very rare	< 1/10,000, (including isolated reports)

Haemorrhage

The most frequent adverse drug reaction associated with reteplase treatment is haemorrhage.

- *very commonly*: bleeding at the injection site (e.g. haematoma)
- *commonly*: as gastrointestinal (haematemesis, melena), gingival or genitourinary bleeding
- *uncommonly*: haemopericardium, retroperitoneal bleeding, cerebral haemorrhage, epistaxis, haemoptysis, eye haemorrhage and ecchymosis were observed.

Reports of intracranial bleeding, many of which are fatal, are of particular concern.

Systolic blood pressure over 160 mmHg before thrombolysis with reteplase was associated with greater risk for cerebral bleeding. The risk of intracranial bleeding and fatal intracranial bleeding increases with increasing age. Blood transfusions were rarely required. Death and permanent disability are not uncommonly reported in patients who have experienced stroke (including intracranial bleeding) and other serious bleeding episodes.

Cardiovascular disorders

As with other thrombolytic agents, the following events have been reported as sequelae of myocardial infarction and / or thrombolytic administration.

- *very commonly*: recurrent ischaemia / angina, hypotension and heart failure / pulmonary oedema
- *commonly*: arrhythmias (e.g. AV block, atrial fibrillation / flutter, ventricular tachycardia / fibrillation, electromechanical dissociation (EMD)), cardiac arrest, cardiogenic shock and reinfarction
- *uncommonly*: mitral regurgitation, pulmonary embolism, other systemic embolism / cerebral embolism and ventricular septal defect

These cardiovascular events can be life-threatening and may lead to death.

Nervous system disorders

- *uncommonly* : cerebral haemorrhage was observed.
- *isolated reports*: events related to the nervous system (e.g. epileptic seizure, convulsion, aphasia, speech disorder, delirium, acute brain syndrome, agitation, confusion, depression, psychosis)

Ischaemic or haemorrhagic cerebrovascular events may be contributing or underlying conditions.

General disorders and administration site conditions

- *very commonly*: haemorrhage at the injection site (e.g. haematoma); a local reaction at injection site for example a burning sensation can occur.

Immune system disorders

- *uncommonly*: hypersensitivity reactions (e.g. allergic reactions)
- *isolated reports*: serious anaphylaxis/ anaphylactoid reactions

Available evidence on reteplase does not indicate an antibody-mediated origin of these hypersensitivity reactions.

4.9 Overdose

In the event of overdosage one might expect depletion of fibrinogen and other blood coagulation components (e.g. coagulation factor V) with a consequent risk of bleeding.

For further information see 4.4 special warnings and special precautions for use, section bleeding.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmaco-therapeutic group: antithrombotic agent, ATC Code: **B 01 A D**

Reteplase is a recombinant plasminogen activator that catalyzes the cleavage of endogenous plasminogen to generate plasmin. This plasminogenolysis occurs preferentially in the presence of fibrin. Plasmin in turn degrades fibrin, which is the main component of the matrix of thrombi, thereby exerting its thrombolytic action.

Reteplase (10+10 U) dose-dependently reduces plasma fibrinogen levels by about 60 to 80 %. The fibrinogen level normalises within 2 days. As with other plasminogen activators a rebound phenomenon then occurs during which fibrinogen levels reach a maximum within 9 days and remain elevated for up to 18 days.

Reductions of plasma levels of plasminogen and α 2-antiplasmin normalise within 1 to 3 days. Coagulation factor V, clotting factor VIII, α 2-macroglobulin, and C1-esterase inhibitor are only slightly reduced and normalise within 1 to 2 days. Plasminogen activator inhibitor 1 (PAI-1) activity can be reduced to around zero, but rapidly normalises within two hours showing a rebound phenomenon. Prothrombin activation fragment 1 levels and thrombin-antithrombin III-complexes increase during thrombolysis indicating thrombin production of which the clinical relevance is unknown.

A large comparative mortality trial (INJECT) in approx. 6000 patients showed that reteplase reduced the incidence of heart failure (secondary efficacy criterion) in a significant manner and was at least equally effective in terms of reducing mortality (primary efficacy criterion) when compared to streptokinase. In two clinical trials aiming primarily at coronary artery patency (RAPID I and II) reteplase was associated with higher early patency rates (primary efficacy criterion), as well as with a lower incidence of heart failure (secondary efficacy criterion) than alteplase (3 hour and "accelerated" dosage regimens). A clinical trial in approximately 15 000 patients comparing reteplase with the accelerated dose regimen of alteplase (GUSTO III) (2:1 randomisation reteplase: alteplase) did not show statistically different results for the primary endpoint of 30-day mortality (reteplase: 7.47 %, alteplase 7.23 %, $p = 0.61$) or for the combined endpoint of 30-day mortality and non-fatal disabling stroke (reteplase: 7.89 %, alteplase 7.88 %, $p = 0.99$). Overall stroke rates were 1.64 % in the reteplase and 1.79 % in the alteplase group. In the reteplase group, 49.4% of these strokes were fatal and 27.1 % were disabling. In the alteplase group 33.0 % were fatal and 39.8 % were disabling.

5.2 Pharmacokinetic properties

Following intravenous bolus injection of 10 + 10 U in patients with acute myocardial infarction reteplase antigen is distributed in plasma with a dominant half-life ($t_{1/2\alpha}$) of 18 ± 5 min and eliminated with a terminal half-life ($t_{1/2\beta}$) of $5.5 \text{ hours} \pm 12.5 \text{ min}$ at a clearance rate of $121 \pm 25 \text{ ml/min}$. Reteplase activity is cleared from the plasma at a rate of $283 \pm 101 \text{ ml/min}$, resulting in a dominant half-life ($t_{1/2\alpha}$) of $14.6 \pm 6.7 \text{ min}$ and a terminal half-life ($t_{1/2\beta}$) of $1.6 \text{ hours} \pm 39 \text{ min}$. Only minor amounts of reteplase were immunologically detected in the urine. Exact data on the main elimination routes for reteplase in humans are not available and the consequences of hepatic or renal insufficiency are not known. Experiments in rats indicate that the liver and the kidneys are the main organs of active uptake and lysosomal degradation.

Additional studies in human plasma samples *in vitro* suggest that complexation with C1-inactivator, α 2-antiplasmin and α 2-antitrypsin contributes to the inactivation of reteplase in plasma. The relative contribution of the inhibitors to inactivation of reteplase decreases as follows: C1-inactivator > α 2-antiplasmin > α 2-antitrypsin.

The half-life of reteplase was increased in patients with AMI as compared to healthy volunteers. An additional increase of half-life of activity in patients with myocardial infarction and severely impaired liver and renal function cannot be excluded, but no clinical data of pharmacokinetics of reteplase in these patients are available. Animal data show that in case of severely impaired renal function with a pronounced increase in serum creatinine and serum urea an increase in half-life of reteplase has to be expected. Mild impairment of renal function did not significantly affect the pharmacokinetic properties of reteplase.

5.3 Preclinical safety data

Acute toxicity studies were performed in rats, rabbits and monkeys. Subacute toxicity studies were performed in rats, dogs and monkeys. The predominant acute symptom after single high doses of reteplase in rats and rabbits was transient apathy shortly after injection. In cynomolgus monkeys, the sedative effect ranged from slight apathy to unconsciousness, caused by a reversible dose-related drop in blood pressure. There was increased local haemorrhage at the injection site.

Subacute toxicity studies did not reveal any unexpected adverse events. In dogs repeated dosing of the human peptide reteplase led to immunologic-allergic reactions. Genotoxicity of reteplase was excluded by a complete battery of tests at different genetic end points *in vitro* and *in vivo*.

Reproductive toxicity studies were performed in rats (fertility and embryo-foetotoxicity study including a littering phase) and in rabbits (embryo-foetotoxicity study, dose-range finding only). In rats, a species insensitive to the pharmacological effects of reteplase, there were no adverse effects on fertility, embryo-foetal development and offspring. In rabbits, vaginal bleedings and abortions possibly associated to prolonged haemostasis, but no foetal abnormalities were noted. A pre- and postnatal toxicity study was not performed with reteplase.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Powder:

Tranexamic acid
di-potassium-hydrogen phosphate
phosphoric acid
sucrose
polysorbate 80

Solvent:

Water for injection

6.2 Incompatibilities

This medicinal product should not be mixed with Heparin and/or acetylsalicylic acid. In the absence of compatibility studies with other medicinal products, Rapilysin must not be mixed with other medicinal products.

6.3 Shelf life

Rapilysin 10 U vials have a shelf-life of 3 years.

When reconstituted as directed, the solution must be used immediately.

Shelf life after reconstitution:

Chemical and physical in-use stability has been demonstrated for 8 hours at 2° to 30 °C after dissolving with water for injection.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.

6.4 Special precautions for storage

Do not store Rapiysin 10 U above 25 °C.

Keep the container in the outer carton in order to protect from light.

6.5 Nature and contents of container

Each pack contains:

2 colorless vials of 10 U of powder with a rubber closure (glass-type I)
2 prefilled syringes with 10 ml solvent for single use (glass type I-Barrel with a tip cap)
2 reconstitution **Spikes**
2 needles 19 G1

6.6 Instructions for use and handling, and disposal

Use aseptic technique throughout.

1. Remove the protective flip-cap from the vial of Rapiysin 10 U and clean the rubber closure with an alcohol wipe.
2. Open the package containing the reconstitution spike, remove both protective caps from the reconstitution spike.
3. Insert the spike through the rubber closure into the vial of Rapiysin 10 U.
4. Take the 10 ml syringe out of the package. Remove the tip cap from the syringe. Connect the syringe to the reconstitution spike and transfer the 10 ml of solvent into the vial of Rapiysin 10 U.
5. With the reconstitution spike and syringe still attached to the vial, swirl the vial gently to dissolve the Rapiysin 10 U powder. **DO NOT SHAKE.**
6. The reconstituted preparation results in a clear, colourless solution. If the solution is not clear and colourless it should be discarded.
7. Heparin and Rapiysin are incompatible when combined in solution. Other incompatibilities may also exist. No other medication should be added to the injection solution.
8. Withdraw 10 ml of Rapiysin 10 U solution back into the syringe. A small amount of solution may remain in the vial due to overfill.
9. Disconnect the syringe from the reconstitution spike and attach the sterile needle provided. The dose is now ready for intravenous administration.
10. No other medication should be injected through the line reserved for Rapiysin either at the same time, or prior to, or following Rapiysin injection. This applies to all products including

heparin and acetylsalicylic acid, which should be administered before and following the administration of reteplase to reduce the risk of re-thrombosis.

11. In those patients where the same line has to be used, this line (including Y-line) must be flushed thoroughly with a 0.9 % sodium chloride or 5 % dextrose solution prior to and following the Rapiysin injection (see 4.2 Posology and method of administration).

7. MARKETING AUTHORISATION HOLDER

Roche Registration Limited
40 Broadwater Road
Welwyn Garden City
Hertfordshire AL7 3 AY
United Kingdom

8. MARKETING AUTHORISATION NUMBER(S)

EU/1/96/018/001

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

09 November 2001

10. DATE OF REVISION OF THE TEXT

ANNEX II

- A. MANUFACTURER OF THE BIOLOGICAL ACTIVE
SUBSTANCE AND MANUFACTURING AUTHORISATION
HOLDER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OF THE MARKETING AUTHORISATION**

**A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE
AND MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH
RELEASE**

Name and address of the manufacturer of the biological active substance

Roche Diagnostics GmbH
Nonnenwald 2
82377 Penzberg
Germany

Name and address of the manufacturer responsible for batch release

Roche Diagnostics GmbH
Sandhofer Strasse 116
68305 Mannheim
Germany

B. CONDITIONS OF THE MARKETING AUTHORISATION

• **CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IMPOSED ON
THE MARKETING AUTHORISATION HOLDER**

Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, 4.2).

• **OTHER CONDITIONS**

The holder of this marketing authorisation must inform the European Commission about the marketing plans for the medicinal product authorised by this decision.

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING

Outer carton

1. NAME OF THE MEDICINAL PRODUCT

Rapilysin 10 U powder and solvent for solution for injection

2. STATEMENT OF ACTIVE SUBSTANCE(S)

Recombinant plasminogen activator, thrombolytic agent
1 vial contains 0.56 g powder for solution for injection with 10 U reteplase

3. LIST OF EXCIPIENTS

Powder:

Tranexamic acid
di-potassium-hydrogen phosphate
phosphoric acid
sucrose
polysorbate 80

Solvent:

Water for injection

4. PHARMACEUTICAL FORM AND CONTENTS

2 colorless vials of 10 U of powder with a rubber closure (glass-type I)
2 prefilled syringes with 10 ml solvent for single use (glass type I-Barell with a tip cap)
2 reconstitution **Spikes**
2 needles 19 G 1

5. METHOD AND ROUTE(S) OF ADMINISTRATION

Intravenous use

6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children

7. OTHER SPECIAL WARNING(S), IF NECESSARY

Use the solution immediately after reconstitution
Please read the package information

8. EXPIRY DATE

EXP

9. SPECIAL STORAGE CONDITIONS

Do not store Rapiysin 10 U above 25 °C
Keep the container in the outer carton in order to protect from light

10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Roche Registration Limited
40 Broadwater Road
Welwyn Garden City
Hertfordshire AL7 3AY
United Kingdom

12. MARKETING AUTHORISATION NUMBER(S)

EU/1/96/018/001


13. MANUFACTURER'S BATCH NUMBER

Batch

14. GENERAL CLASSIFICATION FOR SUPPLY

Medicinal product subject to medical prescription.

15. INSTRUCTIONS ON USE



MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Rapilysin 10 U powder and solvent for solution for injection

2. METHOD OF ADMINISTRATION

Intravenous use

Use the solution immediately after reconstitution

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Batch

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

10 U reteplase

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Label of the syringe

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION

Water for injections

2. METHOD OF ADMINISTRATION

3. EXPIRY DATE

EXP

4. BATCH NUMBER

Batch

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT

10 ml

B. PACKAGE LEAFLET

PACKAGE LEAFLET

Read all of this leaflet carefully before you start using this medicine

- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor or your pharmacist.

In this leaflet:

1. What Rapilysin is and what it is used for
2. Before the doctor gives you Rapilysin
3. How Rapilysin is given
4. Possible side effects
5. Storing Rapilysin
6. Further information

RAPILYSIN 10 U powder and solvent for solution for injection

The active substance of Rapilysin is reteplase. Each vial contains 0.56 g powder for solution for injection with 10 U reteplase (INN).

The other ingredients in the vials are:

Powder:

Tranexamic acid
di-potassium-hydrogen phosphate
phosphoric acid
sucrose
polysorbate 80

Solvent:

10 ml Water for injection (prefilled syringe)

Marketing authorisation holder

Roche Registration Limited
40 Broadwater Road
Welwyn Garden City
Hertfordshire AL7 3AY, United Kingdom

Manufacturer responsible for batch release

Roche Diagnostics GmbH
Sandhofer Str. 116
D-68305 Mannheim
Germany

1. WHAT RAPILYSIN IS AND WHAT IT IS USED FOR

Rapilysin is supplied as a powder and solvent for making a solution for injection. Each pack contains 2 vials with powder for solution for injection, 2 prefilled syringes containing 10 ml water for injection as well as 2 spikes and needles for use while preparing the solution for injection.

Before injection the powder must be dissolved in the water for injection supplied in the prefilled syringes.

Rapilysin (a recombinant plasminogen activator) is a thrombolytic medication used to dissolve blood clots that have formed in certain blood vessels and to restore the blood flow in these blocked vessels (=thrombolysis).

Rapilysin is used after an acute myocardial infarction (heart attack) in order to dissolve the blood clot causing the heart attack. It is given within 12 hours after the onset of symptoms.

2. BEFORE THE DOCTOR GIVES YOU RAPILYSIN

The doctor will ask you questions before giving you Rapilysin, to find out if you have an increased risk of bleeding. Be sure to tell medical staff if you

- are allergic to reteplase or any of the other ingredients of Rapilysin
- have a bleeding disorder
- are taking medicine to thin your blood (oral anticoagulants, e.g. warfarin)
- have a brain tumour or a malformed blood vessel or a vessel wall dilatation (aneurysm) in the brain
- have other tumours associated with an increased risk of bleeding
- have had a stroke
- have had external heart massage within the past 10 days
- have severe uncontrolled high blood pressure (hypertension)
- have an ulcer in the stomach or small intestine
- have enlarged blood vessels in the gullet (oesophagus) (frequently caused by liver disease)
- have severe liver or kidney disease
- have acute inflammation of the pancreas or pericardium (the sac surrounding the heart), or an infection of the heart muscle (bacterial endocarditis)
- have in the past 3 months had severe bleeding, a major injury or major surgery (e.g. coronary artery bypass graft, or surgery or injury to the head or spine), given birth, or had an organ biopsy or other medical / surgical procedure.

Take special care of the following points while Rapilysin is being given:

Bleeding

The most common side effect of Rapilysin is bleeding. Therefore Rapilysin must be given only in the presence and under the instructions of an emergency doctor.

Pay careful attention to all possible bleeding sites (e.g. injection sites). Heparin, which is given together with Rapilysin, may also increase bleeding.

The risks of Rapilysin treatment may be increased if you have any of the following conditions:

- diseases of the blood vessels in the brain

- systolic blood pressure higher than 160 mmHg
- bleeding in the gastrointestinal, urinary or genital tract within the past 10 days
- high likelihood of a blood clot in the heart (e.g. as a result of narrowing of a heart valve or atrial fibrillation)
- septic inflammation of a vein with blood clotting (septic thrombophlebitis) or blocked blood vessels at an infected site
- age over 75 years
- any other condition in which bleeding might be especially dangerous or might occur at a site where it would be difficult to control

At present, little data are available on the use of Rapilysin in patients with diastolic blood pressure higher than 100 mmHg

Abnormal heart beats (arrhythmias)

Thrombolytic treatment may cause the heart to beat irregularly. Therefore tell the medical staff immediately if you

- feel palpitations or an irregular heart beat

Repeated use

At present there is no experience with repeated use of Rapilysin. Therefore, repeated use is not recommended. Antibody formation to the reteplase molecule has not been seen.

Use in children

Safety and effectiveness of Rapilysin in children have not been established. Treatment of children with Rapilysin is not recommended.

Pregnancy

There is no experience with Rapilysin in pregnant women. Therefore it should not be used except in life-threatening situations. You must tell your doctor if you are pregnant or think you are pregnant. Your doctor can tell you the risks and benefits of using Rapilysin during pregnancy.

Breast-feeding

You should not breast-feed your baby during treatment with Rapilysin as it is not known whether Rapilysin is excreted into mother's milk. Mother's milk should be thrown away during the first 24 hours after thrombolytic treatment. Discuss with your doctor when you can take up breast-feeding again.

Using other medicines with Rapilysin:

Heparin and other medicines that thin the blood (anticoagulants) and acetylsalicylic acid (a substance used in many medicines used to relieve pain and lower fever) may increase the risk of bleeding.

Please inform your doctor or pharmacist if you are taking or have recently taken any other medicines, even those not prescribed.

For information on medicines that should not be physically mixed with Rapilysin solution for injection see section 3. How Rapilysin is given.

3. HOW TO USE RAPILYSIN

Rapilysin is usually given in a hospital. The medicine is supplied in vials as a powder for injection. Before use, the powder for injection must be dissolved in the water for injection supplied in the prefilled syringe that is in the package. Do not add any other medication. The resulting solution must be used immediately. The solution must be examined to ensure that only clear, colourless solution is injected. If the solution is not clear and colourless it should be thrown away.

Treatment with Rapilysin 10 U should be started as soon as possible after the symptoms of heart attack begin.

Heparin and Rapilysin cannot be mixed in the same solution. Other medications may also not mix well with Rapilysin. No other medication should be added to the injection solution (see below). Rapilysin should be injected preferably through an intravenous line that is used only for the injection of Rapilysin. No other medication should be injected through the line reserved for Rapilysin, either at the same time, or before or after Rapilysin injection. This applies to all medicines including heparin and acetylsalicylic acid, which are given before and after Rapilysin to reduce the risk of new blood clots forming.

If the same line has to be used, this line (including Y-line) must be flushed thoroughly with a 0.9 % sodium chloride or 5 % dextrose solution before and after the Rapilysin injection.

Dosage of Rapilysin

Rapilysin is given as a 10 U injection followed by a second 10 U injection 30 minutes later (double bolus).

Each injection should be given slowly within 2 minutes. The injection must not be given mistakenly outside the vein. Therefore, be sure to tell the medical staff if you experience pain during the injection.

Heparin and acetylsalicylic acid are given before and after Rapilysin to reduce the risk of new blood clots forming.

Dosage of Heparin

The recommended dose of heparin is 5000 I.U. given as a single injection before Rapilysin, followed by an infusion of 1000 I.U. per hour starting after the second Rapilysin injection. Heparin should be given for at least 24 hours, preferably for 48 - 72 hours, in order to keep aPTT values 1.5 to 2 times normal.

Dosage of Acetylsalicylic Acid

The dose of acetylsalicylic acid given before Rapilysin should be at least 250 mg – 350 mg and should be followed by 75 – 150 mg/day, at least until discharge from hospital.

Instructions for use/handling

Use aseptic technique throughout.

1. Remove the protective flip-cap from the vial of Rapilysin 10 U and clean the rubber closure with an alcohol wipe.
2. Open the package containing the reconstitution spike, remove both protective caps from the reconstitution spike.

3. Insert the spike through the rubber closure into the vial of Rapilysin 10 U.
4. Take the 10 ml syringe out of the package. Remove the tip cap from the syringe. Connect the syringe to the reconstitution spike and transfer the 10 ml of solvent into the vial of Rapilysin 10 U.
5. With the reconstitution spike and syringe still attached to the vial, swirl the vial gently to dissolve the Rapilysin 10 U powder. DO NOT SHAKE.
6. The reconstituted preparation results in a clear, colourless solution. If the solution is not clear and colourless it should be discarded.
7. Heparin and Rapilysin are incompatible when combined in solution. Other incompatibilities may also exist. No other medication should be added to the injection solution.
8. Withdraw 10 ml of Rapilysin 10 U solution back into the syringe. A small amount of solution may remain in the vial due to overfill.
9. Disconnect the syringe from the reconstitution spike and attach the sterile needle provided. The dose is now ready for intravenous administration.
10. No other medication should be injected through the line reserved for Rapilysin either at the same time, or prior to, or following Rapilysin injection. This applies to all products including heparin and acetylsalicylic acid, which should be administered before and following the administration of reteplase to reduce the risk of re-thrombosis.
11. In those patients where the same line has to be used, this line (including Y-line) must be flushed thoroughly with a 0.9 % sodium chloride or 5 % dextrose solution prior to and following the Rapilysin injection.

If more Rapilysin is used than recommended:

In the event of overdosage there may be an increased risk of bleeding.

4. POSSIBLE SIDE EFFECTS

Like all medicines, Rapilysin can have side effects. The most frequent side effects are:

Bleeding

- *mostly:* at the injection site, e.g. blood blister (haematoma)
- *occasionally:* in the digestive tract (e.g. bloody or black vomit, or stools) in the gums or in the urinary or genital tract
- *rarely:* (each in less than 1 %) bleeding around the heart, in the abdomen or the brain, under the skin, from the eyes or nose or as coughed up blood

Patients with systolic blood pressure over 160 mmHg have a greater risk of bleeding in the brain. The risk of intracranial bleeding and fatal intracranial bleeding increases with increasing age. Blood transfusions were rarely required. Death or permanent disability are not uncommon in patients who have a stroke (including bleeding in the brain) or other serious bleeding problem.

Heart and circulation

As with other thrombolytic medications the following side effects have been reported as a result of either the heart attack or the thrombolytic agent.

- *frequently*: chest pain / angina, low blood pressure and heart failure / shortness of breath may reappear
- *occasionally*: abnormal heart beats (arrhythmias), cardiac arrest, circulatory collapse or another heart attack may occur
- *rarely*: damage to the heart or heart valves, or a blood clot in the lung, brain or other part of body may occur

These cardiovascular events can be life-threatening or cause death.

Nervous system

- *isolated cases*: events related to the nervous system (e.g. epileptic seizure, convulsion, speech disorder, confusion)

These may possibly be caused by bleeding or blood clots in the brain.

Injection site

- You may experience a burning sensation when Rapilysin is injected.

Hypersensitivity

- *rarely*: hypersensitivity (e.g. allergic reactions)
- *isolated cases*: severe allergic reaction, causing shock or collapse

Available information on Rapilysin suggests that antibodies are not involved in these reactions.

Be sure to tell hospital staff immediately if any of these symptoms appear. If you notice any side effects not mentioned in this leaflet, please inform your doctor or pharmacist.

5. STORING RAPILYSIN

- Keep out of the reach and sight of children.
- Do not store above 25 °C.
- Keep the container in the outer carton in order to protect from light.
- Do not use after the expiry date stated on the carton and on the label of the vial.
- When dissolved as directed, the solution must be used immediately.

6. FURTHER INFORMATION

For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder.

België/Belgique/Belgien

N.V. Roche S.A.

Tél/Tel: +32 (0) 2 525 82 11

Luxembourg/Luxemburg

(Voir/siehe Belgique/Belgien)

Česká republika

Roche s. r. o.

Tel: +420 - 2 20382111

Magyarország

Roche (Magyarország) Kft.

Tel: +36 - 23 446 800

Danmark

Roche a/s

Tlf: +45 - 36 39 99 99

Malta

(See United Kingdom)

Deutschland

Hoffmann-La Roche AG

Tel: +49 (0) 7624 140

Nederland

Roche Nederland B.V.

Tel: +31 (0) 348 438050

Eesti

Hoffmann-La Roche Ltd

Tel: + 372 - 6 112 401

Norge

Roche Norge AS

Tlf: +47 - 22 78 90 00

Ελλάδα

Roche (Hellas) A.E.

Τηλ: +30 210 61 66 100

Österreich

Roche Austria GmbH

Tel: +43 (0) 1 27739

España

Roche Farma S.A.

Tel: +34 - 91 324 81 00

Polska

Roche Polska Sp.z o.o.

Tel: +48 - 22 608 18 88

France

Roche

Tél: +33 (0) 1 46 40 50 00

Portugal

Roche Farmacêutica Química, Lda

Tel: +351 - 21 425 70 00

Ireland

Roche Products (Ireland) Ltd.

Tel: +353 (0) 1 469 0700

Slovenija

Roche farmacevtska družba d.o.o.

Tel: +386 - 1 360 26 00

Ísland

Roche a/s

c/o Thorarensen Lyf ehf

Tel: +354 530 8000

Slovenská republika

Roche Slovensko, s.r.o

Tel: +421 - 2 52638201 5

Italia

Roche S.p.A.

Tel: +39 - 039 2471

Suomi/Finland

Roche Oy

Puh/Tel: +358 (0) 9 525 331

Κύπρος

Γ.Α.Σταμάτης & Σια Λτδ.

Τηλ: +357 - 22 76 62 76

Sverige

Roche AB

Tel: +46 (0) 8 726 1200

Latvija

Hoffmann-La Roche Ltd.

Tel: +371 - 7 039831

Lietuva

Hoffmann-La Roche Ltd.

Tel: +370 5 2362718

United Kingdom

Roche Products Ltd.

Tel: +44 (0) 1707 366000

This leaflet was last approved on